CLK2: A Drug Target / Disease Biomarker (G1196)

Target Name: CLK2

NCBI ID: G1196

CLK2

CLK2: A Drug Target / Disease Biomarker

CLK2, also known as heat shock protein 2, is a protein that is expressed in a variety of tissues and cells throughout the body. It is a key regulator of the cell's response to heat stress, and is involved in a wide range of cellular processes, including the regulation of DNA replication, cell division, and stress resistance.

Recent studies have identified CLK2 as a potential drug target and biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. CLK2 has also been shown to be involved in a number of cellular processes that are important for human health, including the regulation of aging and the development of neurodegeneration.

One of the key reasons for the potential of CLK2 as a drug target is its involvement in a wide range of cellular processes that are important for human health. For example, CLK2 has been shown to play a role in the regulation of DNA replication, which is critical for the development and maintenance of healthy cells. CLK2 has also been shown to be involved in the regulation of cell division, which is important for the growth and development of tissues and organs.

In addition to its role in cellular processes, CLK2 has also been shown to be involved in a number of diseases and disorders. For example, CLK2 has been associated with a number of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Studies have also shown that CLK2 is involved in the development of cancer, and that it may be a useful biomarker for monitoring the effectiveness of cancer treatments.

Another potential mechanism by which CLK2 may be involved in the development of disease is its role in the regulation of stress resistance. CLK2 has been shown to play a role in the regulation of cellular stress responses, and has been shown to protect cells from the effects of stress in a variety of contexts. For example, studies have shown that CLK2 can help protect cells from the damage caused by ionizing radiation, and that it can also help protect cells from the effects of chemotherapy.

In addition to its potential as a drug target and biomarker, CLK2 has also been shown to have a number of potential therapeutic applications. For example, studies have shown that inhibiting the activity of CLK2 has the potential to treat a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In addition, CLK2 has also been shown to have potential therapeutic applications in the context of aging and the development of neurodegeneration.

Overall, CLK2 is a protein that has a wide range of potential applications as a drug target and biomarker. Its involvement in a number of cellular processes that are important for human health, as well as its association with a variety of diseases and disorders, makes it an attractive target for research and development. Further studies are needed to fully understand the role of CLK2 in these processes and to determine its potential as a therapeutic agent.

Protein Name: CDC Like Kinase 2

Functions: Dual specificity kinase acting on both serine/threonine and tyrosine-containing substrates. Phosphorylates serine- and arginine-rich (SR) proteins of the spliceosomal complex. May be a constituent of a network of regulatory mechanisms that enable SR proteins to control RNA splicing and can cause redistribution of SR proteins from speckles to a diffuse nucleoplasmic distribution. Acts as a suppressor of hepatic gluconeogenesis and glucose output by repressing PPARGC1A transcriptional activity on gluconeogenic genes via its phosphorylation. Phosphorylates PPP2R5B thereby stimulating the assembly of PP2A phosphatase with the PPP2R5B-AKT1 complex leading to dephosphorylation of AKT1. Phosphorylates: PTPN1, SRSF1 and SRSF3. Regulates the alternative splicing of tissue factor (F3) pre-mRNA in endothelial cells. Phosphorylates PAGE4 at several serine and threonine residues and this phosphorylation attenuates the ability of PAGE4 to potentiate the transcriptional activator activity of JUN (PubMed:28289210)

The "CLK2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLK2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets